Guillermo Ortí

1.8k total citations
32 papers, 849 citations indexed

About

Guillermo Ortí is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Guillermo Ortí has authored 32 papers receiving a total of 849 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 11 papers in Oncology and 11 papers in Immunology. Recurrent topics in Guillermo Ortí's work include Hematopoietic Stem Cell Transplantation (15 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Myeloid Leukemia Research (7 papers). Guillermo Ortí is often cited by papers focused on Hematopoietic Stem Cell Transplantation (15 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Myeloid Leukemia Research (7 papers). Guillermo Ortí collaborates with scholars based in Spain, United Kingdom and United States. Guillermo Ortí's co-authors include Carolina García‐Vidal, Pere Barba, Miguel Á. Sanz, Jaime Sanz, David Valcárcel, Pau Montesinos, Guillermo Sanz, Juan D. Cañete, Alfredo Adán and Natalia Borruel and has published in prestigious journals such as Blood, Clinical Infectious Diseases and The Lancet Oncology.

In The Last Decade

Guillermo Ortí

31 papers receiving 841 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guillermo Ortí Spain	12	364	270	226	143	128	32	849
Mirco Belingheri Italy	17	199 0.5×	423 1.6×	182 0.8×	91 0.6×	75 0.6×	30	1.2k
Anna Paola Iori Italy	14	399 1.1×	151 0.6×	108 0.5×	70 0.5×	99 0.8×	38	762
Reiji Fukano Japan	15	186 0.5×	125 0.5×	159 0.7×	114 0.8×	100 0.8×	59	671
Mauricette Michallet France	19	484 1.3×	323 1.2×	266 1.2×	100 0.7×	269 2.1×	73	1.2k
Dong Il Won South Korea	16	232 0.6×	226 0.8×	95 0.4×	87 0.6×	186 1.5×	78	755
Hanyun Ren China	16	618 1.7×	272 1.0×	329 1.5×	45 0.3×	151 1.2×	114	1.1k
Neil A. Lachant United States	16	334 0.9×	99 0.4×	147 0.7×	98 0.7×	83 0.6×	51	990
Mats Remberger Sweden	18	583 1.6×	247 0.9×	398 1.8×	58 0.4×	185 1.4×	37	1.1k
Tarja‐Terttu Pelliniemi Finland	20	450 1.2×	161 0.6×	265 1.2×	89 0.6×	94 0.7×	37	871
Bradley P. Dixon United States	18	345 0.9×	783 2.9×	91 0.4×	161 1.1×	88 0.7×	55	1.4k

Countries citing papers authored by Guillermo Ortí

Since Specialization

Citations

This map shows the geographic impact of Guillermo Ortí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guillermo Ortí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guillermo Ortí more than expected).

Fields of papers citing papers by Guillermo Ortí

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guillermo Ortí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guillermo Ortí. The network helps show where Guillermo Ortí may publish in the future.

Co-authorship network of co-authors of Guillermo Ortí

This figure shows the co-authorship network connecting the top 25 collaborators of Guillermo Ortí. A scholar is included among the top collaborators of Guillermo Ortí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guillermo Ortí. Guillermo Ortí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ortí, Guillermo, Guillaume Dachy, Charlotte Graham, et al.. (2025). Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee. Bone Marrow Transplantation. 60(6). 751–758. 2 indexed citations

García‐Gutiérrez, Valentín, María Teresa Gómez‐Casares, Blanca Xicoy, et al.. (2024). Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia. Frontiers in Oncology. 14. 1405467–1405467. 1 indexed citations

Cabrero, Mónica, Lucía López‐Corral, Isidro Jarque, et al.. (2024). Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial. Bone Marrow Transplantation. 59(3). 359–365. 1 indexed citations

Pérez, Ariadna, Miriam Sánchez‐Escamilla, María Luisa Palacios‐Berraquero, et al.. (2024). Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC). Blood. 144(Supplement 1). 4869–4869.

Hernández‐Boluda, Juan Carlos, María Teresa Gómez‐Casares, Rosa Ayala, et al.. (2023). Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial. Blood. 142(Supplement 1). 1795–1795. 1 indexed citations

López‐Corral, Lucía, Guillermo Martı́n, Francisco J. Márquez‐Malaver, et al.. (2021). Treatment of steroid‐refractory chronic graft‐versus‐host disease with imatinib: Real‐life experience of the Spanish group of hematopoietic transplantation (GETH). Clinical Transplantation. 35(5). e14255–e14255. 4 indexed citations

Fox, María Laura, Irene García‐Cadenas, Ariadna Pérez, et al.. (2020). Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. Leukemia & lymphoma. 61(8). 1823–1832. 2 indexed citations

Ortí, Guillermo, Carlos Palacio, Irene García‐Cadenas, et al.. (2020). Analysis of Cell Subsets in Donor Lymphocyte Infusions from HLA Identical Sibling Donors after Allogeneic Hematopoietic Cell Transplant. Transplantation and Cellular Therapy. 27(1). 53.e1–53.e8. 3 indexed citations

Morales, José María García Ruiz de, L. Puig, E. Daudén, et al.. (2019). Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmunity Reviews. 19(1). 102429–102429. 248 indexed citations

10.

Potter, Victoria, Francesco Grimaldi, Jennifer Clay, et al.. (2019). Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI). Bone Marrow Transplantation. 55(3). 562–569. 11 indexed citations

11.

Ortí, Guillermo, Jaime Sanz, Irene García‐Cadenas, et al.. (2018). Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. Experimental Hematology. 62. 24–32. 9 indexed citations

12.

Steegmann, Juan Luis, Dolors Colomer, María Teresa Gómez‐Casares, et al.. (2017). An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. Journal of Cancer Research and Clinical Oncology. 143(10). 2059–2066. 2 indexed citations

13.

Ortí, Guillermo, Pere Barba, María Laura Fox, et al.. (2016). Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. Experimental Hematology. 48. 1–11. 49 indexed citations

14.

Kharfan‐Dabaja, Mohamed A., Rocío Parody, Janelle Perkins, et al.. (2016). Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplantation. 52(3). 438–444. 8 indexed citations

15.

García‐Cadenas, Irene, Rodrigo Martino, Albert Esquirol, et al.. (2016). Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow Transplantation. 52(1). 107–113. 38 indexed citations

16.

García‐Cadenas, Irene, Rodrigo Martino, Pere Barba, et al.. (2015). Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. Bone Marrow Transplantation. 50(4). 579–584. 45 indexed citations

17.

Schey, Steve, Sarah Brown, Kwee Yong, et al.. (2015). Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. British Journal of Haematology. 170(3). 336–348. 16 indexed citations

18.

Mead, Adam J., Kirsty Thomson, Emma Morris, et al.. (2010). HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood. 115(25). 5147–5153. 46 indexed citations

19.

Montesinos, Pau, Guillermo Martı́n, Jaime Sanz, et al.. (2007). Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 93(1). 67–74. 132 indexed citations

20.

Sanz, Jaime, F Arriaga, Pau Montesinos, et al.. (2007). Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. Bone Marrow Transplantation. 39(9). 555–561. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact